OMS527 / Omeros - LARVOL DELTA

Recent Advances in Medicinal Chemistry of Phosphodiesterase 7 Inhibitors and their Potential Therapeutic Applications. (PubMed, Recent Adv Inflamm Allergy Drug Discov) - "Selective PDE7 inhibitors represent a novel therapeutic class for inflammatory and neurodegenerative diseases. Further research is characterised by immune dysregulation."

Journal • CNS Disorders • Hematological Malignancies • Immunology • Leukemia • Oncology

Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder (Businesswire) - "Omeros Corporation...today announced that it has received a funding commitment from the National Institute on Drug Abuse (NIDA) for the upcoming year...in the amount of $4.02 million for clinical development of its lead orally administered phosphodiesterase 7 (PDE7) inhibitor OMS527 to treat cocaine use disorder (CUD), reducing or eliminating craving and relapse in patients with CUD. This grant will fund the Phase 1b clinical trial in patients with CUD to assess OMS527 safety and efficacy, with initial data readout expected in the fourth quarter of this year."

Financing • P1 data • CNS Disorders

Omeros Corporation Reports First Quarter 2024 Financial Results (Businesswire) - "We continue working toward a resubmission of our biologics license application ('BLA') for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy ('TA-TMA')....We continue to engage with FDA regarding the analysis plan and other expectations for resubmission of our BLA....A manuscript directed to the outcome of narsoplimab treatment in 20 real-world adult and pediatric patients – 19 of whom had high-risk characteristics – is expected to be published soon in the Nature journal Bone Marrow Transplantation....Recent developments regarding OMS527, our phosphodiesterase 7 ('PDE7') inhibitor program focused on addictions and compulsive disorders as well as movement disorders....We expect to complete the preclinical cocaine interaction study by the end of 2024."

Clinical • FDA filing • Preclinical • Anemia • Bone Marrow Transplantation • Hematological Disorders • Nicotine Addiction